Medical Device Alert

MDA/2020/019 Issued: 06 July 2020 at 10:00

Abbott Trifecta / Trifecta GT bioprosthetic aortic heart valves: cases of structural valve deterioration (SVD).

Summary

Manufactured by Abbott – cases of valvular insufficiency and early revision.

Action


- Note precautions regarding proper valve sizing and handling in accordance with the instructions for use (IFU):
  - implantation of an inappropriately large bioprosthesis may result in stent deformation, valvular incompetence, and/or damage to the surrounding tissue
  - do not oversize the valve
  - do not bend the titanium valve stent. The titanium valve stent is not designed as a flexible stent.

- Identify those patients implanted with a 1st generation Trifecta valve and consider implementing enhanced follow-up.

  Due to delays caused by the recent COVID-19 healthcare crisis, we are aware that follow-up and assessments may not take place at normal frequency or in the usual manner. Follow-up recommendations should be risk assessed and completed as soon as possible.

- Report suspected or actual adverse events involving all heart valves through your local incident reporting system and/or your national incident reporting authority as appropriate: England, Scotland, Northern Ireland, Wales. You should also report directly to manufacturers if your local or national systems do not.

Action by
Cardiothoracic surgeons / cardiologists

Deadlines for actions
Actions underway: 03 August 2020
Actions complete: 28 September 2020

Medical Device Safety Officers (in England): ask the manufacturer to add you to their distribution list for field safety notices (FSNs). This is to help with reconciliation.
Device details

Abbott Trifecta Valve:

Abbott Trifecta Valve with Glide Technology (GT):

- 1st generation Trifecta aortic surgical replacement valve, originally manufactured by St. Jude Medical, (now Abbott *), was first CE marked (market approval) in March 2010
- An ‘improved’ Trifecta valve became available from August 2015
- The Trifecta GT valve was CE marked in February 2016

<table>
<thead>
<tr>
<th>Model number</th>
<th>Description</th>
<th>GTIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>TF-19A</td>
<td>TRIFECTA VALVE, 19MM</td>
<td>05414734052016</td>
</tr>
<tr>
<td>TF-21A</td>
<td>TRIFECTA VALVE, 21MM</td>
<td>05414734052023</td>
</tr>
<tr>
<td>TF-23A</td>
<td>TRIFECTA VALVE, 23MM</td>
<td>05414734052030</td>
</tr>
<tr>
<td>TF-25A</td>
<td>TRIFECTA VALVE, 25MM</td>
<td>05414734052047</td>
</tr>
<tr>
<td>TF-27A</td>
<td>TRIFECTA VALVE, 27MM</td>
<td>05414734052054</td>
</tr>
<tr>
<td>TF-29A</td>
<td>TRIFECTA VALVE, 29MM</td>
<td>05414734052061</td>
</tr>
<tr>
<td>TFGT-19A</td>
<td>19mm Trifecta GT Final Package - WR</td>
<td>05415067018205</td>
</tr>
<tr>
<td>TFGT-21A</td>
<td>21mm Trifecta GT Final Package - WR</td>
<td>05415067018212</td>
</tr>
<tr>
<td>TFGT-23A</td>
<td>23mm Trifecta GT Final Package - WR</td>
<td>05415067018229</td>
</tr>
<tr>
<td>TFGT-25A</td>
<td>25mm Trifecta GT Final Package - WR</td>
<td>05415067018236</td>
</tr>
<tr>
<td>TFGT-27A</td>
<td>27mm Trifecta GT Final Package - WR</td>
<td>05415067018243</td>
</tr>
<tr>
<td>TFGT-29A</td>
<td>29mm Trifecta GT Final Package - WR</td>
<td>05415067018250</td>
</tr>
</tbody>
</table>


Problem / background

Since 2010, the MHRA has received 65 UK adverse incident reports relating to 1st generation Trifecta and ‘improved’ Trifecta valves; 5 relate to the Trifecta GT valve.

Most of these reports (57) relate to revision (explant or valve-in-valve repair) due to some form of structural valve deterioration (SVD). The most common reported problems were leaflet damage and/or valvular insufficiency along with a range of other associated concerns. Time to failure, where known, ranged from perioperative to 8 years, with approximately half occurring between 2 to 3 years post implant. Data from our reports does not appear to show any increased tendency for early degeneration associated with valve size. See Appendix B for more information on these reports.

The MHRA has been monitoring the frequency and nature of these reports over time and working with the manufacturer to understand the factors and mechanism of these potential complications.

Data accumulated by Abbott through their Trifecta long-term (10 year) follow-up and durability studies conclude acceptable clinical outcomes. However, the manufacturer acknowledges that the design of the 1st generation Trifecta valve may increase the likelihood of early degeneration. Specifically, the SVD seen may be a result of having a valve design with externally mounted leaflets, in combination with a stent that may be deformed during implant. Improvements to the valve leaflets and reinforcement of the stent which were implemented in later designs, are expected to reduce this risk (see Appendix B).
Abbott has cited important factors that may influence the risk of SVD in these valves, including implant technique (in their technical bulletin) together with other precautions listed in the associated IFU.

As well as creating abnormal stress and strain to the valve, oversizing the Trifecta/Trifecta GT valve could also result in direct contact between the stent post and the aortic wall, which may result in decreased valve durability due to abrasion or fusion of the posts with the aortic wall.

Recently published independent case report studies and articles (though not RCTs - see Appendix B for more information), have also helped to draw attention to this issue. One new significant paper based on data from the Finnish National Database (FinnValve registry), reports a SVD rate disparity between Trifecta and a comparator valve. Abbott confirm that all 13 Trifecta revision events reported in this paper, relate to the 1st generation Trifecta vale.

It is likely that most cases of early valve failure such as those outlined above, will be detected either during routine patient surveillance or hospital admission. However, MHRA is recommending that patients who received the 1st generation Trifecta valves are identified and considered for more frequent (enhanced) follow-up*. This advice is due to the potential increased risk of valve deformation during implant, as well as accumulating signals from published case report studies and articles. The form and extent of this follow-up (above the standard annual) should be determined locally on a case-by-case basis.

2017 was the last year that the 1st generation Trifecta was sold in the U.K. Their manufacturing dates range from 09 December 2014 to 15 June 2015, with a shelf life of 4 years. Hence the last valves would have expired in June 2019.

The MHRA encourages cardiothoracic surgeons and cardiologists to continue to report all adverse incident reports, including early events of SVD / NSVD (non-structural valve deterioration), to both the manufacturer and the MHRA.

* Due to delays caused by the recent COVID-19 healthcare crisis, we are aware that follow-up and assessments may not take place at normal frequency or in the usual manner. Follow-up recommendations should be risk assessed and completed as soon as possible.

Manufacturer contacts

Name: Luke Gilbertson – Quality Assurance and Regulatory Compliance Specialist (UK & Ireland)
Tel: 01213060482
Email: michael.gilbertson@abbott.com

Distribution

If you are responsible for cascading these alerts in your organisation, these are our suggested distribution lists.

Trusts (NHS boards in Scotland)
CAS and NICAS liaison officers for onward distribution to all relevant staff including:

- Cardiologists
- Cardiology departments
- Cardiology nurses
- Cardiology, directors of
- Cardiothoracic departments
- Cardiothoracic surgeons
- Cardiothoracic surgery directors
• Coronary care departments
• Coronary care nurses
• Medical directors

**General Practice**
For onward distribution to all relevant staff including GPs, Practice Managers and Practice Nurses.

**Note:** We are sending this alert to GPs for information only, in case patients ask them about the contents of this notice. GPs do not need to take any action.

**Independent distribution**

**Establishments registered with the Care Quality Commission (CQC) (England only)**
• Hospitals in the independent sector

Please note: CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Central Alerting System (CAS) by sending an email to: safetyalerts@mhra.gov.uk and requesting this facility.

**Enquiries**

**England**
Send enquiries about this notice to MHRA, quoting reference number MDA/2020/019 or 2019/003/019/468/002

**Technical aspects**
Alexander McLaren, MHRA
Tel: 020 3080 6000
Email: DSS-TM@mhra.gov.uk

**Clinical aspects**
Devices Clinical Team, MHRA
Tel: 020 3080 7274
Email: dct@mhra.gov.uk

To report an adverse incident involving a medical device in England use the Yellow Card reporting page.

**Northern Ireland**
Northern Ireland Adverse Incident Centre (NIAIC), CMO Group, Department of Health (Northern Ireland)
Tel: 028 9052 3868
Email: niaic@health-ni.gov.uk

To report an adverse incident involving a medical device in Northern Ireland use the forms on the website. Alerts in Northern Ireland are distributed via the NICAS system.

**Scotland**
Incident Reporting and Investigation Centre (IRIC), Health Facilities Scotland, NHS National Services Scotland
Tel: 0131 275 7575
Email: nss.iric@nhs.net
To report an adverse incident involving a medical device in Scotland, email IRIC to request a webform account.
For more information, or if you can’t access the webform, visit the website: [how to report an adverse incident](#).

**Wales**
Population Healthcare Division, Welsh Government
Tel: 03000 255278 or 03000 255510
Email: Haz-Aic@gov.wales

To report an adverse incident involving a medical device in Wales, use the [Yellow Card reporting page](#) and follow specific advice for reporting in Wales in MDA/2004/054 (Wales).

MHRA is a centre of the Medicines and Healthcare products Regulatory Agency, an executive agency of the Department of Health and Social Care.
© Crown Copyright 2020
Addressees may take copies for distribution within their own organisations
Dear Clinician,

This Technical Bulletin is intended to summarize the key design changes made to the Trifecta valve from the first-generation Trifecta valve to the second-generation valve reflecting Abbott’s commitment to the quality and continuous improvement of our medical devices. In addition, this Technical Bulletin provides a summary of the clinical outcomes achieved at 10 years post-implant for the first-generation Trifecta valve.

The first-generation Trifecta valve was introduced into clinical use in 2007, designed for supra-annular implantation and excellent hemodynamic performance. To ease the implant procedure and provide added handling protection to the stent and leaflets, a second-generation Trifecta valve with Glide Technology (Trifecta GT) was introduced in 2016.

The Trifecta GT valve has the following enhancements:

1) A streamlined holder with legs positioned in front of the leaflets for added protection during valve insertion and knot tying;
2) Internal backstops within the holder to protect the stent posts from deforming during valve insertion;
3) A softer sewing cuff that conforms more easily to the annulus and which minimizes suture drag;
4) An additional titanium band that protects the stent base geometry and provides enhanced fluoroscopic visibility;
5) Optimized leaflet suturing process along the stent post to reduce leaflet stress;
6) Increased leaflet tissue tensile strength achieved by using a collagen fiber alignment technology, which ensures circumferential fiber alignment to resist fatigue related leaflet tissue degradation.

At the same time the Trifecta GT valve was being developed, an improved version of the first-generation Trifecta valve was produced which included the same manufacturing processes utilized on Trifecta GT to improve the leaflet suturing pattern along the stent post, and the leaflet collagen fiber alignment. These two improvements, which are listed as items #5 and #6 above, were introduced to both Trifecta and Trifecta GT to enhance the durability of the leaflet tissue when combined with appropriate valve sizing and handling.

To further ease the implant procedure and improve access to the sewing cuff while suturing, a new holder is being introduced to the Trifecta GT valve in early 2020. The new holder has legs with a narrower footprint to permit easier access to the sewing cuff during placement of sutures while retaining the same protective features of the original Trifecta GT holder. The following figures illustrate (1) the evolution of the Trifecta valve timeline; and (2) the specific enhancements introduced with Trifecta GT.
Figure 1: The evolution of the Trifecta valve timeline

Figure 2: The specific enhancements introduced with Trifecta GT

Bioprosthetic heart valves have a potential for developing either non-structural valve dysfunction (NSVD) or structural valve deterioration (SVD) over the lifetime of the valve. NSVD is characterized as any abnormality not intrinsic to the
valve itself (such as entrapment by pannus, tissue, or suture; paravalvular leak; and inappropriate sizing or positioning) that may result in stenosis or regurgitation of the operated valve or hemolysis. SVD is characterized as changes intrinsic to the valve itself (such as calcification, leaflet fibrosis, leaflet tear, or flail leaflet) that may result in stenosis or regurgitation due to irreversible valve degeneration. NSVD may commonly be attributed to technical factors encountered at the time of valve implant, while SVD may commonly be attributed to biological factors and mechanical stress which develop over a longer implant duration.

To assess the long-term clinical outcomes of the first-generation Trifecta valve, Abbott conducted a Long-Term Follow-UpStudy5. The 10-year follow-up from this study was recently completed and demonstrated excellent hemodynamic performance at 10-years (mean transvalvular gradient of 15.6 mmHg). At 10 years post implant, the freedom from all-cause mortality was 70%, the freedom from surgical explant due to SVD was 87%, and the freedom from any reintervention (surgical explant or transcatheter valve-in-valve intervention) due to SVD was 75%. The freedom from any reintervention and all-cause mortality at 10 years post-implant was 51%, which is consistent with the rate reported for other bioprosthetic aortic valves6,7. In choosing a bioprosthetic aortic valve, the potential for SVD should be balanced against the potential hemodynamic and survival benefits of the Trifecta valve. In comparison to the first-generation Trifecta valve, the Trifecta GT valve has additional features that make the valve easier to implant and potentially reduce the occurrence of NSVD and SVD over the lifetime of the valve.

In summary, the Trifecta and Trifecta GT valves have been designed and continuously improved with the aim to optimize performance by easing valve implantation and minimizing leaflet tissue damage. These design characteristics, in combination with proper valve sizing and handling in accordance with the IFU (e.g., oversizing, excessive force used during insertion, and handling of the leaflets with surgical instruments which are noted as precautions in the IFU), minimize the potential for developing NSVD and SVD, leading to the best clinical outcomes.

If you have any questions about this communication, please contact your local Abbott representative.

Sincerely,

Kara Carter
Divisional Vice President, Quality Structural Heart

References
APPENDIX B: Background information

A. Summary of reports received by MHRA

It is important to recognise that the numbers recorded by the MHRA has limitations. Though manufacturers are legally required to submit serious reports of this type to the MHRA, with regards to clinicians and members of the public, it is a passive (voluntary) system. It is recognised that there will inevitably be under-reporting. Though the system cannot provide an accurate UK total number of events, or a precise calculation of the incidence or prevalence rate, it does serve to act as an indicator to undertake further exploration.

Further details of the 65 reports given below:

1. Reported Problem (note more than one problem could be cited per report):

   - 31 reports reference some form of regurgitation (transvalvular leak) or insufficiency.
   - 19 reports refer to calcification, and or fibrous / pannus thickening.
   - 12 cite stenosis / obstruction to blood flow or high gradient.
   - 8 remark on deformed / distorted (valve / stent post) or a faulty valve with leaflets not coapting.
   - 1 references the stent post being ‘fused’ to the aortic wall.

2. Implant duration:

<table>
<thead>
<tr>
<th>Duration</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unknown</td>
<td>12</td>
</tr>
<tr>
<td>Peri-operative</td>
<td>6</td>
</tr>
<tr>
<td>1 to 24 months</td>
<td>6</td>
</tr>
<tr>
<td>2 to 3 years</td>
<td>27</td>
</tr>
<tr>
<td>4 to 7 years</td>
<td>10</td>
</tr>
<tr>
<td>over 7 years</td>
<td>4</td>
</tr>
</tbody>
</table>

B. Summary of event data provided by Abbott Vascular

The manufacturer has assisted the MHRA and shared information on the numbers of Trifecta reports associated with structural valve deterioration (SVD), fibrous-calcific structural valve deterioration (FCSVD), non-calcific leaflet tear (NCLT), as well as non-structural valve deterioration (dysfunction) (NSVD).

Note: the SVD rate is the FCSVD and NCLT rates combined.
Structural valve deterioration (SVD) can be defined as changes intrinsic to the valve itself (such as calcification, leaflet fibrosis, leaflet tear, or flail leaflet) that may result in stenosis or regurgitation due to irreversible valve degeneration. Two known modes of SVD observed with tissue heart valves are fibrous-calcific structural valve deterioration (FCSVD) and a non-calcific leaflet tear (NCLT).

FCSVD is characterized by fibrous thickening of the leaflet tissue and/or infiltration of the leaflet tissue with calcium deposits resulting in decreased leaflet mobility (aortic stenosis). Echocardiography demonstrates an elevated transvalvular gradient but may sometimes also show aortic insufficiency secondary to incomplete leaflet coaptation due to leaflet stiffening.

NCLT is characterized by thinning of the leaflet tissue with loss and disruption of collagen fibers at the tear site with absence of leaflet fibrosis and calcification. Echocardiography demonstrates aortic insufficiency without an elevated transvalvular gradient.

Non-structural valve deterioration (dysfunction) (NSVD) is characterized as any abnormality not intrinsic to the valve itself (such as entrapment by pannus, tissue, or suture; paravalvular leak; and inappropriate sizing or positioning) that may result in stenosis or regurgitation of the operated valve or haemolysis.

1 Capodanno, Davide, Anna S. Petronio, Bernard Prendergast, Helene Eltchaninoff, Alec Vahanian, Thomas Modine, Patrizio Lancellotti et al. ‘Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).’ European heart journal 38, no. 45 (2017): 3382-3390.


C. Modifications to manufacturing

Abbott have conducted ‘primary factor modifications’ to the manufacturing sewing process (with the aim of reducing leaflet stress) implemented in July 2015. Similarly, adjustments have been made to reduce tissue variation and improve collagen fibre alignment consistency in order to improve tensile strength and enhance resistance to fatigue. These changes are applicable to both the ‘improved’ Trifecta and the Trifecta GT valves. Deformation of the Trifecta valve stent base also has the potential to result in acute valvar regurgitation from inadequate leaflet coaptation (rather than leaflet tear). The design of the Trifecta GT valve has been further supplemented with a ‘titanium band’.

D. Literature

Fausto Biancari, MD, PhD, Antti Valtola, MD, Tatu Juvonen, MD, PhD, Annastiina Husso, MD, PhD, Sebastian Dahlbacka, MD, PhD, Teemu Laakso, MD, Maina P. Jalava, MD, Tuomas Tauriainen, MD, PhD, Tuomas Ahvenvaara, MD, Eeva-Maija Kinnunen, MD, PhD, Matti Niemelä, MD, PhD, Timo Mäkikallio, MD, PhD, Markku Eskola, MD, PhD, Marko P.O. Virtanen, MD, Pasi Maaranen, MD, Stefano Rosato, MSc, Vesa Anttila, MD, PhD, Antti Vento, MD, PhD, Juhani Airaksinen, MD, PhD, Peter Raivio, MD, PhD. Trifecta versus Perimount Magna Ease Aortic Valve Prostheses. Ann Thorac Surg. 2020 Feb 12;S0003-4975(20)30194-6. doi: 10.1016/j.athoracsur.2019.12.071.

Daisuke Kaneyuki, MD, Hiroyuki Nakajima, MD, PhD, Toshihisa Asakura, MD, PhD, Akihiro Yoshitake, MD, PhD, Chiho Tokunaga, MD, PhD, Masato Tochii, MD, PhD, Jun Hayashi, MD, Akitoshi Takazawa, MD, Hiroaki Izumida, MD, and Atsushi Ichiguchi, MD, PhD. Early First-Generation Trifecta Valve Failure: A Case Series and a Review of the Literature Ann Thorac Surg 2020;109:86-93) 2020 by The Society of Thoracic Surgeons.

Shinichi Fukuhara, MD, Suzuna Shioml, BS, Bo Yang, MD, PhD, Karen Kim, MD, MS, Steven F. Bolling, MD, Jonathan Haft, MD, Paul Tang, MD, Francis Pagani, MD, PhD, Richard L. Prager, MD, Stanley Chetcuti, MD, P. Michael Grossman, MD, Himanshu J. Patel, MD, and G. Michael Deeb, MD - Early Structural Valve Degeneration of Trifecta Bioprosthesis - Ann Thorac Surg 2020;109:720-7

Ka Yan Lam, MD, Bart Koene, MD, Naomi Timmermans, MD, Mohamed Soliman-Hamad, MD, PhD, and Albert van Straten, MD, PhD - Reintervention After Aortic Valve Replacement: Comparison of 3 Aortic Bioprostheses - Ann Thorac Surg 2020;

Masanori Hara, MD, Muneyasu Kawasaki, PhD, Keiichi Tokuhiro, PhD, Toru Kameda, MD, Yoshio Nunoi, MD, Yoshinori Watanabe,PhD Leaflet Tear of Trifecta Bioprosthesis - Heart, Lung and Circulation(2019) 28, 660–661

Shin-ichi Ohki and Hirotaka Sato - Early Valve Dysfunction of Bioprosthetic Valves: Review of Reports Yoshio Misawa, Annals of Cardiovascular Surgery, 2018 | Volume 1 | Issue 1 | Article 1009


Manoras Mathew Chengalath, Bhaskar Ranganathan and Jose Chacko Periappuram - Is Commissural region tear an Achilles’ heel of the Trifecta aortic bioprosthesis? - Asian Cardiovascular & Thoracic Annals 2018, Vol. 26(1) 67

Ankur Kalra, MD, Hasan Rehman, MD, Mahesh Ramchandani, MD, Colin M. Barker, MD, Gerald M. Lawrie, MD, Ross M. Reul, MD, Michael J. Reardon, MD, and Neal S. Kleiman, MD - Early Trifecta valve failure: Report of a cluster of cases from a tertiary care referral center. The Journal of Thoracic and Cardiovascular Surgery c, October 2017 Volume 154, Number 4

Masaki Hamamoto, MD, PhD, Taira Kobayashi, MD, Masamichi Ozawa, MD, and Kosuke Yoshimura, MD - Pure Cusp Tear of Trifecta Bioprosthesis 2 Years after Aortic Valve Replacement - Ann Thorac Cardiovasc Surg 2017; 23: 157–160